Breast Cancer
Conditions
Keywords
HER2-positive Breast Cancer
Brief summary
This study will assess the objective response rate (ORR), safety, progression-free survival (PFS) , overall survival (OS), 6-month survival rate, 12-month survival rate, 18-month survival rate, 24-month survival rate, disease control rate (DCR), clinical benefit rate (CBR), duration of response (DOR) and Time to Response (TTR). Injection of A166 for HER2-positive patients with refractory unresectable locally advanced or metastatic breast cancer who have failed previous ADC drug therapy.
Interventions
DRUGInjection of A166
4.8 mg/kg for each 21 (±3) -day cycle
Sponsors
Fudan University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This study adopts an open research design and selects patients with refractory HER2-positive unresectable locally advanced or metastatic breast cancer who have failed previous ADC drug treatment. The patients who met the enrollment conditions were treated with injection of A166.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 1\. Male or female patient ≥ 18 years and ≤ 75 years when signing the informed consent form; 2. Breast cancer patients by histopathology and/or cytology documented, including: a) Participants with unresectable locally advanced or metastatic breast cancer; b) Evaluated or tested as HER2-positive expression. The definition of HER2 positive in this study: immunohistochemistry (IHC) was 2+ and confirmed by fluorescence in situ hybridization (FISH), or IHC was 3+; 3. Have received at least 3 targeted therapies for locally advanced or metastatic disease, including: 1. Disease progression after receiving at least 1 trastuzumab-containing (including a biosimilar of trastuzumab on the market)-based treatment; 2. After receiving at least one anti-HER2 tyrosine kinase inhibitor (lapatinib or pyrrotinib)-based treatment plan, the disease progresses or cannot tolerate toxic and side effects; 3. The disease progresses or cannot tolerate toxic and side effects after receiving treatment with antibody-conjugated drugs targeting HER2 (such as T-DM1 or other ADCs); Note: Adjuvant therapy and anti-HER2 therapy used in the neoadjuvant treatment stage before radical treatment are not counted, but recurrence or metastasis occurs during the last anti-HER2 medication period or within one year after the end, it can be regarded as a plan. 4\. Have previously received taxanes to treat breast cancer;
Exclusion criteria
* 1\. Serious or uncontrollable heart diseases that require treatment, including: 1. Congestive heart failure graded 3 or 4 by the New York College of Cardiology (NYHA); 2. Unstable angina pectoris that cannot be controlled by drugs; 3. Myocardial infarction occurred within 6 months before the first administration of the study treatment; 4. Severe arrhythmia requiring medical treatment (except for atrial fibrillation or paroxysmal supraventricular tachycardia); 2. Baseline measurement, QTc interval, male\> 450 msec, female\> 470 msec; 3. Clinically active interstitial lung disease; 4. Patients with primary central nervous system (CNS) malignant tumors or CNS metastases that have failed local treatment; for asymptomatic brain metastases, or with stable clinical symptoms and no need for steroids and other brain metastases within 4 weeks before the first administration of the trial drug Treated patients can be included in the group; 5. Those who are known to have a history of hypersensitivity to other monoclonal antibodies or allergic to A166 and its components for injection; 6. Those who have permanently discontinued trastuzumab due to any toxicity;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate（ORR） | 2 years | ORR is defined as the percentage of subjects who have achieved complete response and partial response according RECIST 1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate(DCR) | 2 years | DCR is defined as cases where objective remission(assessed as complete remission or partial remission according RECIST 1.1 standard) or stable disease during the study. |
| Clinical benefit rate(CBR) | 2 years | CBR is defined as the proportion of patients with a complete or partial response or with stable disease according RECIST 1.1 |
| Progression-free survival(PFS) | 2 years | PFS is defined as the time between date of first dose of study therapy and date of progression or death according RECIST 1.1. |
| Time to response(TTR) | 2 years | TTP is defined as the time between randomization and objective tumor progression according RECIST 1.1; TTP does not include death |
| Overall survival(OS) | 2 years | Overall survival(OS) is defined as the time from first dose of study therapy to the date of death(any case).Subjects who are alive censored at the last known time that the subject was alive. |
| Duration of rate(DOR) | 2 years | DOR is defined the time between the first tumor evaluation for CR or PR and the first evaluation for PD(Progressive Disease) or death from any cause according RECIST 1.1. |
Contacts
Primary ContactXichun Hu, Doctor
Backup ContactJian Zhang, Master
Outcome results
None listed